Table 1 Baseline characteristics of the included studies
First author | Publication year | Study type | No. of patients | Country | Antiviral therapy | Outcomes | Risk |
|---|---|---|---|---|---|---|---|
Zhigang Ren | 2020 | RCT | 20 | China | FNC vs No antiviral therapy | TFNANC, AEs | High |
Renato Martins da Silva | 2023 | RCT | 312 | Brazil | FNC vs No antiviral therapy | TFNANC, AEs | Low |
Paula Cabral | 2022 | RCT | 180 | Brazil | FNC vs No antiviral therapy | TFNANC, AEs | Low |
Kaican Zong | 2023 | R | 585 | China | FNC vs No antiviral therapy | Mortality | Moderate |
Minxue Shen | 2023 | R | 452 | China | FNC vs No antiviral therapy | Mortality, ICU admission, IMV/ECMO | Moderate |
Guangtong Deng | 2023 | R | 562 | China | FNC vs RN | Mortality, ICU admission, IMV/ECMO | Moderate |
Qinqin Zhao | 2023 | R | 286 | China | FNC vs RN | Mortality, TFNANC, AEs | Moderate |
Hui Yang | 2023 | R | 804 | China | FNC vs No antiviral therapy | AEs | Moderate |
Jiasheng Shao | 2023 | R | 686 | China | FNC vs No antiviral therapy | Mortality | Serious |
Ru Chen | 2023 | R | 198 | China | FNC vs No antiviral therapy | Mortality, ICU admission, IMV/ECMO | Moderate |
Shunlai Shang | 2023 | R | 364 | China | FNC vs No antiviral therapy | AEs | Moderate |
Wenmei Chen | 2023 | R | 207 | China | FNC vs No antiviral therapy | TFNANC, AEs | Moderate |
Xinjie Han | 2023 | R | 856 | China | FNC vs No antiviral therapy | Mortality | Moderate |
Yating Dian | 2023 | R | 456 | China | FNC vs RN | Mortality, ICU admission, IMV/ECMO | Moderate |
Yuan Gao | 2023 | R | 134 | China | FNC vs RN | TFNANC | Moderate |
Yiling Zhou | 2023 | R | 1154 | China | FNC vs No antiviral therapy | Mortality | Unclear |
Yuming Sun | 2023 | R | 490 | China | FNC vs No antiviral therapy | Mortality, ICU admission, IMV/ECMO | Moderate |